Answers are grounded in this paper and cite their sources.
Collectively, these results reveal the potential of SPR741 in combination with clarithromycin and erythromycin as a clinical therapy for refractory infections caused by XDR A. baumannii.
No takes yet. Share an insight, caveat, or question.
Li et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: